SCHEMBL15573239

SCHEMBL15573239

CNC(=O)c1cc(Oc2ccc(C(C)NC(=O)Nc3cc(Cl)c(Cl)cc3Cl)cc2)ccn1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 12/20 0.52
BRAF P15056 7/20 0.52
KDR P35968 6/20 0.52
EPHX2 P34913 4/20 0.52
RET P07949 4/20 0.52
MAPK14 Q16539 4/20 0.52
ABL1 P00519 3/20 0.52
EPHA2 P29317 3/20 0.52
MAP3K20 Q9NYL2 3/20 0.52
RIPK2 O43353 2/20 0.52
ABCB11 O95342 2/20 0.52
HTR1A P08908 2/20 0.52
PDGFRB P09619 2/20 0.52
ADORA3 P0DMS8 2/20 0.52
KIT P10721 2/20 0.52
FGFR1 P11362 2/20 0.52
PDGFRA P16234 2/20 0.52
FLT1 P17948 2/20 0.52
MAOA P21397 2/20 0.52
EPHA1 P21709 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16990699 0.90 RAF1 (0.45) RAF1BRAFKDREPHX2RET
SCHEMBL15573129 0.88 RAF1 (0.62) RAF1BRAFKDREPHX2RET
SCHEMBL15575322 0.84 KMT2A (0.62) RAF1BRAFKDREPHX2RET
SCHEMBL15573188 0.84 RAF1 (0.58) RAF1BRAFKDREPHX2RET
SCHEMBL13603827 0.83 KDR (0.60) RAF1BRAFKDREPHX2RET
SCHEMBL15575325 0.82 DDR2 (0.59) RAF1BRAFKDREPHX2RET
SCHEMBL17000014 0.81 LMNA (0.62) RAF1BRAFKDREPHX2RET
SCHEMBL170976 0.81 RAF1 (0.80) RAF1BRAFKDREPHX2RET
SCHEMBL17000015 0.81 RAF1 (0.56) RAF1BRAFKDREPHX2RET
SCHEMBL18068294 0.80 BRAF (0.67) RAF1BRAFKDREPHX2RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150225369-A1 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS MERCK PATENT GMBH (DE) 2015-08-13 US claimed
EP-2890380-A2 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS Merck Patent GmbH (DE) 2015-07-08 EP claimed
WO-2014032755-A2 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS MERCK PATENT GMBH (DE) 2014-03-06 WO claimed
US-20150225369-A1 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS MERCK PATENT GMBH (DE) 2015-08-13 US disclosed
EP-2890380-A2 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS Merck Patent GmbH (DE) 2015-07-08 EP disclosed
WO-2014032755-A2 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS MERCK PATENT GMBH (DE) 2014-03-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150225369-A1 DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS DDR2, DDR1, DDRGK1 RAF1 3072/4885BRAF 3224/4885KDR 404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.